Finance

Lists
Why is NVS up ၂.၃၈%?
Dive Deeper
NVS:NYSE
Novartis
၁၅၀.၃၈ US$
+၂.၃၈%
(+၃.၅၀) 1D
၁၅၀.၃၈ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၁၅, GMT-၄ ၁၆:၀၀:၀၈  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVS...
Open
၁၅၀.၃၂ US$
High
၁၅၁.၈၃ US$
Low
၁၄၉.၆၄ US$
Mkt. cap
ဋေ ၃.၀၈ သ
Avg. vol.
၂.၃၁ သန်း
Volume
၀.၀၀
Dividend
၃.၁၅%
Quarterly dividend
၁.၁၉ US$
Ex-dividend date
၂၀၂၆ မတ် ၁၀
P/E ratio
၂၂.၇၁
52-wk high
၁၇၀.၄၆ US$
52-wk low
၁၂၁.၅၇ US$
EPS
၆.၆၂ US$
Beta
၀.၃၉
Shares outstanding
၂၀၃.၄၈ ဋေ
No. of employees
၈ သောင်း
Open
၁၅၀.၃၂ US$
High
၁၅၁.၈၃ US$
Low
၁၄၉.၆၄ US$
Mkt. cap
ဋေ ၃.၀၈ သ
Avg. vol.
၂.၃၁ သန်း
Volume
၀.၀၀
Dividend
၃.၁၅%
Quarterly dividend
၁.၁၉ US$
Ex-dividend date
၂၀၂၆ မတ် ၁၀
P/E ratio
၂၂.၇၁
52-wk high
၁၇၀.၄၆ US$
52-wk low
၁၂၁.၅၇ US$
EPS
၆.၆၂ US$
Beta
၀.၃၉
Shares outstanding
၂၀၃.၄၈ ဋေ
No. of employees
၈ သောင်း
News stories
From web sources and news partners
MarketsMojo
MarketsMojo
·
ပြီးခဲ့သည့် ၁ နာရီ
Novartis India Ltd Upgraded to Buy on Strong Technical and Financial Performance
TradingKey
TradingKey
·
ပြီးခဲ့သည့် ၁၄ နာရီ
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement
ad-hoc-news.de
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၂၀ နာရီ
Bank of America keeps CHF 150.00 target for Novartis stock
Quiver Quantitative
Quiver Quantitative
·
ပြီးခဲ့သည့် ၁ ရက်
Why Novartis (NVS) Stock Is Up Today
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis
CEOVasant Narasimhan
Employees၇.၅၃ သောင်း
Founded၁၉၉၆ မတ် ၇
Headquartersဘေဆဲလ်, Basel City, ဆွစ်ဇာလန်
Sector-
Analyst ratings
Based on 7 analysts giving stock ratings to NVS in the past 3 months
Buy
Buy
3
Hold
3
Sell
1
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for NVS in the last 3 months.
Highest
Current ၁၅၀.၃၈ US$
၁၈၀.၈၂ US$ (+၂၀.၂၄%)
Average
၁၅၈.၄၀ US$ (+၅.၃၃%)
Lowest
၁၃၆.၀၀ US$ (-၉.၅၆%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sachin Jain
Bank of America Securities
Buy
Maintained
၁၅၀.၀၀ CHF
-၀.၃%
10/12/2026
Thibault Boutherin
Morgan Stanley
Buy
Maintained
၁၅၆.၀၀ US$
+၃.၇%
10/06/2026
Rajesh Kumar
HSBC
Hold
Upgraded
၁၃၆.၀၀ US$
-၉.၆%
09/10/2026
Steve Scala
TD Cowen
Hold
Maintained
၁၈၀.၀၀ US$
+၁၉.၇%
09/08/2026
Kerry Holford
Berenberg Bank
Hold
Maintained
၁၄၇.၀၀ US$
-၂.၂%
07/27/2026
Jasper Hellweg
Argus Research
Buy
Maintained
၁၇၀.၀၀ US$
+၁၃%
07/24/2026
Unknown Analyst
Goldman Sachs
Sell
Maintained
၁၃၉.၀၀ US$
-၇.၆%
07/22/2026
Justin Smith
Bernstein
Hold
Initiated
-
-
03/19/2026
David Toung
Argus Research
Buy
Upgraded
၁၈၀.၀၀ US$
+၁၉.၇%
03/11/2026
Next call ၁၁ ရက်အတွင်း
အောက် ၂၇ အင်္ဂါ, ၁၈:၄၀
Fiscal period
Q3 2026
- / ၂.၂၄ US$
Revenue / Est. (USD)
- / ဋေ ၁.၄၆ ထ
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
ဋေ ၁.၄၄ ထ
ဋေ ၁.၃၉ ထ
ဋေ ၁.၃၅ ထ
ဋေ ၁.၅၀ ထ
Cost of goods sold
၃၅၃.၅၀ ဋေ
၃၅၄.၂၀ ဋေ
၃၄၃.၈၀ ဋေ
၃၆၇.၈၀ ဋေ
Cost of revenue
၃၅၃.၅၀ ဋေ
၃၅၄.၂၀ ဋေ
၃၄၃.၈၀ ဋေ
၃၆၇.၈၀ ဋေ
Research and development expenses
၂၈၆.၄၀ ဋေ
၂၈၃.၇၀ ဋေ
၂၇၈.၅၀ ဋေ
၂၇၃.၉၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၃၃၀.၄၀ ဋေ
၃၄၃.၆၀ ဋေ
၃၁၃.၇၀ ဋေ
၃၂၃.၁၀ ဋေ
Operating expense
၆၂၃.၈၀ ဋေ
၆၄၆.၃၀ ဋေ
၅၉၆.၄၀ ဋေ
၆၀၉.၇၀ ဋေ
Total operating expenses
၉၇၇.၃၀ ဋေ
ဋေ ၁.၀၀ ထ
၉၄၀.၂၀ ဋေ
၉၇၇.၅၀ ဋေ
Operating income
၄၅၈.၅၀ ဋေ
၃၈၅.၅၀ ဋေ
၄၁၂.၂၀ ဋေ
၅၁၇.၆၀ ဋေ
Other non operating income
-၇.၀၀ သန်း
-၁၃.၀၀ ကုဋေ
၄.၀၀ သန်း
၁.၉၀ ကုဋေ
EBT including unusual items
၄၁၉.၆၀ ဋေ
၃၂၁.၈၀ ဋေ
၃၈၃.၉၀ ဋေ
၄၂၆.၉၀ ဋေ
EBT excluding unusual items
၄၂၉.၃၀ ဋေ
၃၄၉.၂၀ ဋေ
၃၇၈.၀၀ ဋေ
၄၇၃.၁၀ ဋေ
Income tax expense
၂၆.၆၀ ကုဋေ
၈၁.၄၀ ကုဋေ
၆၈.၃၀ ကုဋေ
၁၀၁.၂၀ ဋေ
Effective tax rate
၆.၃၄%
၂၅.၃၀%
၁၇.၇၉%
၂၃.၇၁%
Other operating expenses
၇.၀၀ ကုဋေ
၁၉.၀၀ ကုဋေ
၄.၂၀ ကုဋေ
၁၂.၇၀ ကုဋေ
Net income
၃၉၂.၈၀ ဋေ
၂၄၀.၉၀ ဋေ
၃၁၅.၆၀ ဋေ
၃၂၆.၄၀ ဋေ
Net profit margin
၂၇.၃၆%
၁၇.၃၈%
၂၃.၃၄%
၂၁.၈၃%
Earnings per share
၂.၂၅
၂.၀၃
၁.၉၉
၂.၄၁
Interest and investment income
-
၃၇.၃၀ ကုဋေ
-
-
Interest expense
-၂၈.၁၀ ကုဋေ
-၃၀.၄၀ ကုဋေ
-၃၄.၃၀ ကုဋေ
-၄၆.၂၀ ကုဋေ
Net interest expenses
-၂၈.၁၀ ကုဋေ
၆.၉၀ ကုဋေ
-၃၄.၃၀ ကုဋေ
-၄၆.၂၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၅၇၇.၅၀ ဋေ
၄၉၅.၆၀ ဋေ
၅၂၃.၈၀ ဋေ
၆၂၉.၉၀ ဋေ
Gain or loss from assets sale
၈.၁၀ ကုဋေ
၈.၀၀ ကုဋေ
-၁၅.၉၀ ကုဋေ
-၂၄.၇၀ ကုဋေ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ